SHMN - ein Generika-Gigant entsteht
Seite 1 von 1 Neuester Beitrag: 20.01.14 23:11 | ||||
| Eröffnet am: | 19.01.14 14:57 | von: Tuedi2005 | Anzahl Beiträge: | 14 |
| Neuester Beitrag: | 20.01.14 23:11 | von: Chalifmann3 | Leser gesamt: | 4.078 |
| Forum: | Hot-Stocks | Leser heute: | 4 | |
| Bewertet mit: |  | |||
In 2012, SHMN was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people"s lives in every corner of the world, the company has U.S. headquarters in Buena Park, Calif., with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.
Research and development activities capitalize on the company"s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.
To ensure regulatory compliance, SHMN continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, SHMN is well positioned to continue its rapid growth.
www.sohm.com
Recently Developed 11 New OTC Products in the U.S.
Developing Innovative Product Pipeline of Cosmeceuticals
Leveraging High Expertise in Numerous Drug Delivery Technologies
Operating in Rapidly Expanding Pharmaceuticals Market
Voted Fastest Growing Prescription Drug Manufacturer in 2012
SOHM Posts FH2013 Financial Results, Provides Full-Year Outlook
Revenues in the First-Half of 2013 Expected to Exceed Total Revenues Achieved in Full-Year 2012
BUENA PARK, CA--(Marketwired - Nov 19, 2013) - SOHM, Inc. (PINKSHEETS: SHMN), a company that manufactures and markets generic pharmaceuticals, nutraceutical and cosmeceuticals covering all major treatment categories, today announces its financial results for the first six months of 2013, as well as provides guidance for the full year.
SOHM reports revenue growth of 116 percent for the first six months of 2013, compared to revenues in the comparable period of 2012. Nine months revenue of $1,539,055 has already surpassed revenue of $1,296,450 achieved during the full year of 2012. By end of fiscal year 2013, SOHM projects revenue growth of more than 55 percent as compared to 2012.
Shailesh Shah, president and CEO of SOHM, stated, "SOHM is confident for its outlook for the year 2013 and beyond for its continued growth due to focused approach. This year we have introduced to market two exciting new skin care product lines to U.S. consumers, as well as a unique protein supplement in India."
The launch of I-Prolec protein supplement in the Indian market adds weight to SOHM's confidence in its product offerings, and creates a new and valuable stream of revenue generation.
"Success of our I-Prolec supplement, Salic-2 Gel and Fohm by Sohm face wash products, and nine over-the-counter medicines packaged in travel packs, support the projected financial growth and profitability we expect to achieve during 2014," Shah stated.
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Besides generic drugs, SOHM also has manufacturing facilities for food supplements and cosmetics. The Company has global headquarters located in California, U.S., with manufacturing facilities in India. SOHM exports generic pharmaceuticals worldwide, placing a heavy focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. For more information visit the company's website at: www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Und gerade auch mit einem Markt wie Indien sollten sich Generika massenhaft verkaufen lassen.
Da sollte ein weiteres Wachstum eigentlich vorprogrmmiert sein.
In den letzten Woche scheinen hier ja auch schon einige Investoren aufmerksam geworden sein.
Trotzdem ist die aktuelle Bewertung ein Witz imo.
http://ih.advfn.com/p.php?pid=nmona&article=60088577
SOHM Posts FH2013 Financial Results, Provides Full-Year Outlook
Revenues in the First-Half of 2013 Expected to Exceed Total Revenues Achieved in Full-Year 2012
BUENA PARK, CA--(Marketwired - Nov 19, 2013) - SOHM, Inc. (PINKSHEETS: SHMN), a company that manufactures and markets generic pharmaceuticals, nutraceutical and cosmeceuticals covering all major treatment categories, today announces its financial results for the first six months of 2013, as well as provides guidance for the full year.
SOHM reports revenue growth of 116 percent for the first six months of 2013, compared to revenues in the comparable period of 2012. Nine months revenue of $1,539,055 has already surpassed revenue of $1,296,450 achieved during the full year of 2012. By end of fiscal year 2013, SOHM projects revenue growth of more than 55 percent as compared to 2012.
Shailesh Shah, president and CEO of SOHM, stated, "SOHM is confident for its outlook for the year 2013 and beyond for its continued growth due to focused approach. This year we have introduced to market two exciting new skin care product lines to U.S. consumers, as well as a unique protein supplement in India."
The launch of I-Prolec protein supplement in the Indian market adds weight to SOHM's confidence in its product offerings, and creates a new and valuable stream of revenue generation.
"Success of our I-Prolec supplement, Salic-2 Gel and Fohm by Sohm face wash products, and nine over-the-counter medicines packaged in travel packs, support the projected financial growth and profitability we expect to achieve during 2014," Shah stated.
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Besides generic drugs, SOHM also has manufacturing facilities for food supplements and cosmetics. The Company has global headquarters located in California, U.S., with manufacturing facilities in India. SOHM exports generic pharmaceuticals worldwide, placing a heavy focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. For more information visit the company's website at: www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
www.otcmarkets.com/stock/SHMN
SHMN ist jedenfalls kein Fake oder Geldbeschaffungsmaschine wie so viele OTC-Buden.
